ライフサイエンスコーパス: HPV vaccine

1 independently associated with not receiving HPV vaccine.

2 ditions were not less likely to initiate the HPV vaccine.

3 reported receipt of at least one dose of the HPV vaccine.

4 d men and the approval of a second, bivalent HPV vaccine.

5 idate combination preventive and therapeutic HPV vaccine.

6 eling the potential impact of a prophylactic HPV vaccine.

7 red to compose a broadly efficacious genital HPV vaccine.

8 CCs after the first dose of the quadrivalent HPV vaccine.

9 nts after administration of the quadrivalent HPV vaccine.

10 ain partial cross-protection by the bivalent HPV vaccine.

11 o timing and number of doses of quadrivalent HPV vaccine.

12 asurable preventable disease outcome for the HPV vaccine.

13 t a moderately high level of knowledge about HPV vaccine.

14 HPV types than is achieved with the licensed HPV vaccines.

15 ases potentially preventable by prophylactic HPV vaccines.

16 f cervical cancer from the second-generation HPV vaccines.

17 to our understanding of the early impact of HPV vaccines.

18 types and the efficacy of current and future HPV vaccines.

19 s have implications for the design of future HPV vaccines.

20 ed in the 4-valent and 9-valent prophylactic HPV vaccines.

21 forts are needed to realise the potential of HPV vaccines.

22 the quadrivalent and nonavalent prophylactic HPV vaccines.

23 prophylactic bivalent human papillomavirus (HPV) vaccine.

24 drivalent and bivalent human papillomavirus (HPV) vaccines.

25 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

26 reviously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to as "addition

27 with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.

28 Among girls who received 2 doses of HPV vaccine 6 months apart, responses to HPV-16 and HPV-

29 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years who had

30 e data support vaccination with quadrivalent HPV vaccine across a broad range of baseline subject cha

31 ation for prophylactic human papillomavirus (HPV) vaccines, adult women who remain at risk of cervica

32 Uptake of human papillomavirus (HPV) vaccine among girls in the Dutch immunization progr

33 of parents and health care providers toward HPV vaccine and critically evaluate controversial and ch

34 11-88x5 adjuvanted with alum or the licensed HPV vaccines and challenged intravaginally with HPV6, HP

35 items, not attending a school meeting about HPV vaccine, and not knowing anyone with cancer.

36 B2) sensitivities to cross-neutralization by HPV vaccine antibodies compared to that of the A1 sublin

37 tial of L2 as a second-generation preventive HPV vaccine antigen.

38 The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1

39 rly is decreasing and women who received the HPV vaccine are due to attend screening for the first ti

40 Human papillomavirus (HPV) vaccines are ideally administered before HPV exposu

41 Human papillomavirus (HPV) vaccines are recommended for girls prior to sexual

42 mized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261) or 2 doses a

43 patient received 3 doses of the quadrivalent HPV vaccine at 0, 2, and 6 months in 2013, and both pati

44 n was used to obtain prevalence estimates of HPV vaccine awareness and initiation adjusted for sociod

45 ently, there are three licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the

46 Safe and effective HBV and HPV vaccines, based on virus-like particles, are commerc

47 Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self

48 reported receipt of at least one dose of the HPV vaccine before the age of 26 years (29.2% in women a

49 HPV vaccine can be delivered with high coverage in schoo

50 s were randomly assigned (1:1) to receive an HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart, Belgi

51 at 6 or 12 months in the group who received HPV vaccine compared with the control group.

52 three FDA-approved multivalent prophylactic HPV vaccines composed of virus-like particles (VLPs).

53 The human papillomavirus (HPV) vaccines consist of major capsid protein (L1) virus

54 A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) w

55 Availability of a human papillomavirus (HPV) vaccine could have an important public health impac

56 human papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adolescents has increased

57 HPV vaccine coverage was 84.7% for dose 1, 81.4% for dos

58 Our findings also suggested that 2 doses of HPV vaccine delivered at 0 and 12 months might afford si

59 nd January 2010) assessing 4 schedules of an HPV vaccine delivered in 21 schools to 903 adolescent gi

60 uscular injection of 3 doses of quadrivalent HPV vaccine delivered on a standard dosing schedule (at

61 sponse to quadrivalent human papillomavirus (HPV) vaccine delivered at 0, 2, and 6 months in young ad

62 ervical cancer worldwide and is the focus of HPV vaccine development efforts.

63 ed and therefore represent ideal targets for HPV vaccine development.

64 analysis, 809 girls who received at least 1 HPV vaccine dose had valid serum measurements 1 month af

65 onse following reduced human papillomavirus (HPV) vaccine doses has not been determined.

66 States completing the human papillomavirus (HPV) vaccine doubled.

67 round of HPV screening, possibly dampened by HPV vaccine effect; in this study, although the point es

68 Human papillomavirus (HPV) vaccine effectiveness and herd protection are not w

69 specified, end-of-study combined analysis of HPV vaccine efficacy studies for prevention of cervical

70 of an HPV16/18 prevalence of 12% before the HPV vaccine era, extended catch-up vaccination for femal

71 dose to a two-dose protocol for the licensed HPV vaccines, especially in younger adolescents (aged 9-

72 of clinically approved human papillomavirus (HPV) vaccines, Females United to Unilaterally Reduce End

73 What is the potential of HPV vaccines for primary prevention?

74 vaccine antigen in the human papillomavirus (HPV) vaccine Gardasil.

75 tions at 6 months were 33.4% (82/248) in the HPV vaccine group and 31.6% (95/298) in the control grou

76 ates at 12 months were 48.8% (86/177) in the HPV vaccine group and 49.8% (110/220) in the control gro

77 ing the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 d

78 Clinical trials on the viral-like particle HPV vaccines have good safety profiles and promising eff

79 Since preventative HPV vaccines have not been widely used in many countries

80 Both HPV vaccines have shown very good efficacy and safety.

81 alent and quadrivalent human papillomavirus (HPV) vaccines have been introduced in most developed cou

82 Although available human papillomavirus (HPV) vaccines have high efficacy against incident infect

83 Human papillomavirus (HPV) vaccines have the potential to prevent cervical can

84 il cases reported that they would accept the HPV vaccine if it were offered again (97% and 93% respec

85 on the recent successes of immunotherapy and HPV vaccine immune prevention.

86 Quadrivalent HPV vaccine immunogenicity delivered on 3 alternative do

87 ing HPV types in CIN2+ may be used to assess HPV vaccine impact.

88 rs of vaccine introduction, indicating early HPV vaccine impact.

89 mmunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >3

90 eness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States.

91 014, more than 57 countries had included the HPV vaccine in their national health programmes.

92 ist regarding the safety of the quadrivalent HPV vaccine in this context.

93 al to be used for monitoring of prophylactic HPV vaccines in the future.

94 Since licensure of the human papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adol

95 s for the quadrivalent human papillomavirus (HPV) vaccine in Tanzanian schoolgirls.

96 Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effec

97 f Cervarix or Gardasil human papillomavirus (HPV) vaccines in adults infected with the human immunode

98 Effectiveness of human papillomavirus (HPV) vaccines in the context of both guidelines, which r

99 the potential value of human papillomavirus (HPV) vaccines, information concerning the incidence and

100 nal research articles describing barriers to HPV vaccine initiation and completion among US adolescen

101 morbidities; we estimated the prevalence of HPV vaccine initiation in cancer survivors versus the US

102 Conclusion HPV vaccine initiation rates in cancer survivors are low

103 ears postcompletion of therapy); we assessed HPV vaccine initiation, sociodemographic and clinical ch

104 ese data provide baseline information before HPV vaccine introduction.

105 The implementation of the HPV vaccine is a tremendous milestone in our effort towa

106 HPV vaccine is also recommended for MSM, people living w

107 Prophylactic HPV vaccine is available for primary prevention.

108 This study demonstrated the HPV vaccine is effective in a real-world setting of high

109 HPV vaccine is recommended routinely for 11- or 12-year-

110 In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and

111 The quadrivalent human papillomavirus (HPV) vaccine is recommended for all girls and women 9 to

112 ratio and interviewed about cervical cancer, HPV vaccine knowledge and reasons why they might have re

113 A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types tar

114 iminary evidence suggests that recipients of HPV vaccines might derive prophylactic benefits from one

115 P < .001); survivors were more likely to be HPV vaccine-naive than general population peers (odds ra

116 The introduction of HPV vaccines necessitates the estimation of the populati

117 25 years, 84.4% reported having heard of the HPV vaccine; of these, 28.5% had initiated HPV vaccinati

118 cent girls in Vietnam, administration of the HPV vaccine on standard and alternative schedules was im

119 pact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related t

120 substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-related cervical disease i

121 ts 9-26 years old randomized to quadrivalent HPV vaccine or placebo in phase 2/3 studies were analyze

122 rs' perceived lack of insurance coverage for HPV vaccine (OR, 6.6; 95% CI, 3.9 to 11.0; P < .001), ma

123 HPV vaccines prevent infection with HPV 16 and 18, which

124 Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 1

125 Decreasing human papillomavirus (HPV) vaccine prices makes scaling up of vaccination prog

126 Human papillomavirus (HPV) vaccine programs may decrease the morbidity and mor

127 Bivalent and quadrivalent HPV vaccines protect against 66% of HPV-associated cervi

128 Human papillomavirus (HPV) vaccines provide an opportunity to reduce the incid

129 ence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dos

130 died the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasi

131 By preventing HPV infection, quadrivalent HPV vaccine (qHPV) reduces risk of anal cancer/precancer

132 58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.

133 currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions

134 een after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associa

135 We conducted a case control study of HPV vaccine receivers and non-receivers within a phase I

136 ong men who have sex with men (MSM); and (6) HPV vaccine recommendations.

137 objective was to show that the quadrivalent HPV vaccine reduced the incidence of external genital le

138 concentrations >/=29 months after 3 doses of HPV vaccine regardless of dose-timing, and extended sche

139 Adolescent uptake of human papillomavirus (HPV) vaccine remains low.

140 Recent developments in HPV vaccine research are reviewed.

141 He received the quadrivalent HPV vaccine resulting in clearance of all lesions after

142 he 3-dose quadrivalent human papillomavirus (HPV) vaccine series (HPV-6, -11, -16, -18) is immunogeni

143 The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe

144 equent among subjects receiving quadrivalent HPV vaccine than among those receiving placebo (57% vs.

145 Second-generation HPV vaccines that protect against additional oncogenic H

146 success stories such as the well-publicised HPV vaccine, the challenges remain significant.

147 Administration of HPV vaccine to HPV-naive women, and women who are alread

148 dle-free, and affordable formulations of the HPV vaccine to overcome the socioeconomic barriers assoc

149 es and concerns as barriers to providing the HPV vaccine to patients.

150 Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by c

151 ars old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis.

152 en (n=5,871) in the NCI-sponsored Costa Rica HPV Vaccine Trial's prevaccination enrollment visit were

153 present thinking about primary endpoints for HPV vaccine trials as developed at an experts workshop c

154 rovide insights in future efforts, including HPV vaccine trials.

155 dently associated with seroprevalence of any HPV vaccine type among both females and males, and pover

156 12.2% among males; the seroprevalence of any HPV vaccine type increased with age, reaching 42.0% amon

157 ic blacks had a higher seroprevalence of any HPV vaccine type than that observed for non-Hispanic whi

158 For any HPV vaccine type, the seroprevalence was 32.5% among fem

159 nefit of vaccinating boys, and potential for HPV-vaccine-type elimination.

160 revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16, and 18, was

161 HPV vaccine types 6 and 11 (low-risk types) and 16 and 1

162 mory, suggesting possible protection against HPV vaccine types after a single dose of 4vHPV.

163 However, the prevalence of HPV vaccine types was relatively low.

164 We evaluated HPV vaccine uptake patterns over 2008-2011 by race/ethni

165 6 years) = 1.34) were associated with higher HPV vaccine uptake.

166 to vaccination may help to increase overall HPV vaccine uptake.

167 hose who initiated the human papillomavirus (HPV) vaccine versus those who did not.

168 measured 1 month after the third dose of the HPV vaccine was administered; GMT was determined by type

169 The immunogenicity of quadrivalent HPV vaccine was comparable among subjects with differing

170 The bivalent HPV vaccine was efficacious in prevention of incident an

171 Willingness to recommend the HPV vaccine was moderate, with 69.7% intentionally initi

172 tched analyses, exposure to the quadrivalent HPV vaccine was not associated with significantly higher

173 The quadrivalent HPV vaccine was well tolerated by both patients and had

174 The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9- through 26-year-

175 Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccina

176 oses (at 0, 1, and 6 months) of the bivalent HPV vaccine were identified in the vaccination registrat

177 Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and

178 ection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against H

179 or HPV-6/11 infection with the quadrivalent HPV vaccine will result in a high neutralizing antibody

180 e decentralised with the hope that effective HPV vaccines will be made increasingly available in low-

181 re widespread availability of a prophylactic HPV vaccine would be useful.